公司资料
Unicycive Therapeutics 股价、新闻与催化剂
- 股票代码:
- UNCY
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
5.57 USD (+1.09%)
收盘价
最后更新: 2026年8月17日
193M USD
市值
股价为何变动
As of Aug 17, 2026, UNCY closed up 1.09% at $5.57. No new same-company headline was identified in the current news window.
公司概览
Kidney Disease Therapeutics
Unicycive Therapeutics develops medicines for conditions associated with chronic kidney disease.
Oxylanthanum Carbonate
Oxylanthanum carbonate is an oral phosphate binder for hyperphosphatemia in dialysis patients. It is designed to achieve phosphate control with a lower pill burden than commonly used therapies.
Regulatory Resubmission Path
The FDA's prior review did not identify efficacy or safety deficiencies but required resolution of manufacturing-facility issues. A third-party vendor inspection is the key step preceding NDA resubmission.
未来催化剂
- Completion of the FDA inspection of the third-party oxylanthanum carbonate manufacturing facility.
- Resubmission of the oxylanthanum carbonate NDA following a successful facility inspection.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。